The estimated prevalence of trigeminal neuralgia from this tertiary care center in Karnataka, India, is 0.007%. There was a female dominance regarding the reported symptoms that triggered pain ...

“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for the treatment of moderate-to-severe pain that is a non-opioid and carries less risks of addiction than opioids. Journavx ...

Daniel Robinson is a writer based in Greenville, N.C. with expertise in auto insurance, loans, warranty options and more. Away from the keyboard, Daniel spends time with his wife and son, plays ...

This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years. “Today’s approval is an important public health ...

The FDA's sign-off on the medication comes as the agency says it is prioritizing supporting the development of non-opioid pain treatment. Suzetrigine is the first non-opioid analgesic – or ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) and manufactured by biotech company Vertex ...

The company also conducted a third study of people with a wider range of pain-related conditions—both surgical and non-surgical—affecting the head, neck, shoulder, knee, foot, and ankle.